A detailed history of Encompass More Asset Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Encompass More Asset Management holds 4,818 shares of GILD stock, worth $453,421. This represents 0.15% of its overall portfolio holdings.

Number of Shares
4,818
Previous 4,294 12.2%
Holding current value
$453,421
Previous $295 Million 37.11%
% of portfolio
0.15%
Previous 0.21%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$66.59 - $83.99 $34,893 - $44,010
524 Added 12.2%
4,818 $404 Million
Q2 2024

Jul 26, 2024

BUY
$63.15 - $72.88 $26,965 - $31,119
427 Added 11.04%
4,294 $295 Million
Q1 2024

May 10, 2024

BUY
$71.58 - $87.29 $83,462 - $101,780
1,166 Added 43.17%
3,867 $283 Million
Q4 2023

Feb 15, 2024

BUY
$73.27 - $83.09 $197,902 - $224,426
2,701 New
2,701 $219 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Encompass More Asset Management Portfolio

Follow Encompass More Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Encompass More Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Encompass More Asset Management with notifications on news.